Prevention and control of seasonal influenza with vaccines:
ACIP recommendations for the United States, 2025-26 season

Key updates for 2025-26 season Vaccine composition changes All influenza vaccines available in the United States during the 2025-26 season will be trivalent, containing hemagglutinin derived from:  H1N1 component: A/Victoria/4897/2022 (H1N1)pdm09-like virus (egg-based) or A/Wisconsin/67/2022 (H1N1)pdm09-like virus (cell culture-based and recombinant)  H3N2 component: A/Croatia/10136RV/2023 (H3N2)-like virus (egg-based) or A/District of Columbia/27/2023 (H3N2)-like virus (cell culture-based and recombinant) – Updated from 2024-25  Influenza B component: B/Austria/1359417/2021 (Victoria lineage)-like virus  FluMist self-administration approval FDA approved FluMist (LAIV3) for self-administration by recipients aged 18-49 years or administration by caregivers aged ≥18 years for children and adolescents aged 2-17 years. This will be available through the FluMist Home program during the 2025-26 season, allowing consumers to order vaccine for home delivery under temperature-controlled conditions after eligibility screening.  Flublok age expansion FDA expanded Flublok (RIV3) approval from persons aged ≥18 years to ≥9 years, based on noninferiority immunogenicity studies comparing children and adolescents aged 9-17 years with adults aged 18-49 years. The...